Colombia vs Seychelles: Statin use vs. average non-HDL cholesterol levels
Colombia
3.7
in 2018
Seychelles
3.7
in 2018
Colombia rank
12th
Seychelles rank
12th
Statin use vs. average non-HDL cholesterol levels over time
- Colombia
- Seychelles
How they compare
Colombia currently reports 3.7 against 3.7 in Seychelles, a difference of 0.
Across all 39 years both countries report, Seychelles has been ahead every year.
Colombia ranks 12th and Seychelles ranks 12th of 191 countries.
Seychelles has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Colombia | Seychelles | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.82 | 3.92 | 0.1 | Seychelles |
| 1990s | 3.9 | 4.08 | 0.18 | Seychelles |
| 2000s | 3.85 | 3.98 | 0.13 | Seychelles |
| 2010s | 3.74 | 3.78 | 0.0333 | Seychelles |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Colombia or Seychelles?
- Colombia, at 3.7 against 3.7 in Seychelles as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Colombia and Seychelles?
- 0, with Colombia ahead.
- How many years of comparable data are there for Colombia and Seychelles?
- 39 years are reported by both, from 1980 to 2018.
- How do Colombia and Seychelles rank globally for statin use vs. average non-hdl cholesterol levels?
- Colombia ranks 12th and Seychelles ranks 12th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.